|
Aug 3
|
2 Beaten-Down Stocks With Incredible Upside Potential
|
|
Jul 31
|
This Stock Is Up by 800% This Year -- but Is It a Buy?
|
|
Jul 28
|
Abivax Announces Closing of $747.5 Million Public Offering
|
|
Jul 25
|
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
|
|
Jul 24
|
Abivax (ABVX) Skyrockets 586% to New High on Promising Drug Trial, Bullish Analyst Outlooks
|
|
Jul 24
|
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
|
|
Jul 24
|
Abivax announces trading resumption of its ordinary shares on Euronext Paris
|
|
Jul 24
|
Rocket lays off staff; Abivax capitalizes on immune drug data
|
|
Jul 24
|
Abivax stock surges 580% following dual Phase III success in UC
|
|
Jul 24
|
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
|
|
Jul 23
|
Abivax Announces Launch of Public Offering
|
|
Jul 23
|
Abivax Hits The Stratosphere, Up Nearly 600%, On 'Potentially Disruptive' Results
|
|
Jul 23
|
Top Midday Gainers
|
|
Jul 23
|
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study
|
|
Jul 23
|
Abivax stock soars on trial data for ulcerative colitis drug
|
|
Jul 22
|
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
|
|
Feb 21
|
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
|
|
Oct 7
|
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
|
|
Oct 2
|
Abivax Highlights Obefazimod Ulcerative Colitis Program With New Data to be Presented at the UEG Week 2023
|
|
Sep 29
|
Abivax Files Registration Statement for Proposed Initial Public Offering in the United States
|